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Predictors of response to intra-articular steroid
injections in knee osteoarthritis—a systematic review
Nasimah Maricar1, Michael J. Callaghan1, David T. Felson1 and
Terence W. O’Neill1
Abstract
Objective. IA steroid injections (IASIs) have been shown to relieve pain in knee OA and are widely used in
clinical practice. There is, however, evidence of some variation in response. Knowledge of predictors of
response could aid in the selection of patients for this therapy. The aim of this systematic review was to
determine factors associated with response to IASI in knee OA.
Methods. Medline, Embase, AMED, CINAHL, Web of Science and Cochrane Central Registers for
Controlled Trials up to January 2012 were searched with additional hand searches of relevant articles.
Studies included were those that involved adults diagnosed with knee OA in whom IASIs were adminis-
tered and factors that predicted treatment response were investigated.
Results. Eleven publications meeting these criteria were reviewed and relevant information extracted. It
was not possible to pool the results because of the different predictors studied, variable outcome meas-
ures, different criteria for symptom change and missing data. Given the relative paucity of data and small
heterogeneously designed studies, it was difficult to identify predictors of response. Data from individual
publications, although not consistent across studies, suggest that the presence of effusion, withdrawal of
fluid from the knee, severity of disease, absence of synovitis, injection delivery under US guidance and
greater symptoms at baseline may all improve the likelihood of response to IASI.
Conclusion. Further larger-scale studies using standardized methods are required to characterize pre-
dictors of response and should focus on synovitis, effusion, pain and structural severity of disease. Such
data would help in better targeting therapy to those most likely to benefit.
Key words: osteoarthritis of the knee, clinical trials, treatment response, predictors of response, systematic
review.
Introduction
OA is the most common chronic joint disease worldwide.
IA steroid injection (IASI) has been widely used in the
management of symptomatic knee OA, one of the most
commonly affected joints. There is evidence of short-term
benefit of IASI to provide pain relief for up to 34 weeks
[118]. However, there is disagreement on the long-term
benefit of therapy [2, 19].
Data from the published trials indicate, however, that
there is significant variation in both the magnitude and
duration of response to steroid injections. As an example,
the magnitude of pain improvement measured using a
visual analogue scale (VAS) on a 0100 scale varied be-
tween a mean change of 16.235.7 mm [8, 11, 14, 2022],
while the duration of pain relief varied between 1 and 8
weeks [4, 5, 8, 11, 14, 20, 21]. The reason for variation in
response is unclear, but may be related to disease fac-
tors, treatment or patient-related factors. If factors con-
sistently associated with response to steroids could be
identified, steroid injections might be better targeted to
those most likely to respond. We undertook a systematic
review of the published literature to determine whether
there are patient-, treatment- or disease-related factors
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that predict either the magnitude or duration of response
to IASI in knee OA.
Materials and methods
Search strategies
Publications that contained reports of factors that may
predict response from IASI in knee OA were identified
from searching six databases up to January 2012:
Medline (from 1948 onwards), Embase (1974 onwards),
AMED (1985 onwards), Cumulative Index to Nursing and
Allied Health Literature (CINAHL) Plus (1937 onwards),
Web of Science (1950 onwards) and Cochrane Central
Registers for Controlled Trials. The search was conducted
with close reference to the users’ guides for undertaking
electronic searches of the medical literature [23]. There
were no language restrictions. The databases were
searched individually for all possible terms and combin-
ations of terms to accommodate differences in the search
engines. All medical subject heading (MeSH) searches
were explored when possible. The key terms used in com-
bination (AND) were knee osteoarthritis, intra-articular (IA),
corticosteroids, injection, trials and predictors. The
reference lists of all identified papers were scanned
and, in addition, the contents pages of Arthritis and
Rheumatism, Annals of the Rheumatic Diseases and
Arthritis Care and Research for the past 10 years were
hand-searched for other relevant publications.
Study selection criteria
Publications considered were those that included adults
with knee OA based on the ACR clinical classification
criteria for OA [24] or based on the study having stated
patients had knee OA from detailed clinical and/or radio-
graphic assessment of the knee joint. Also, we included
studies where IASIs were administered and factors that
predicted treatment response investigated. These factors
included the presence of effusion, clinical synovitis, syn-
ovial hypertrophy, severity of knee OA (based on radio-
graphic grade), presence of knee pain, knee range of
movement, muscle strength, stiffness, local tenderness,
heat, duration of symptoms and functional, anxiety and
depression indices. Outcome measures considered im-
portant for evaluating clinical predictors of steroid injec-
tions were improvement in pain. Studies could be either
clinical trials in which predictors of response were pre-
sented or observational studies that included information
on predictors of response.
Quality assessment
The quality of randomized controlled trials (RCTs) included
was graded using the Jadad score [25], a validated and
widely used assessment tool [26]. It comprises a maximum
of 5 points, where a point each is awarded if a trial uses
randomization, double blinding and provides appropriate
and correct description of the randomization and the
double blinding, and gives a description of drop-outs or
withdrawal of participants. The Consolidated Standards of
Reporting Trials (CONSORT) statement was referred to
when deciding if the randomization and double-blinding pro-
cedures were appropriate to score the relevant points [27,
28]. We considered trials as of low quality when scores were
42, whereas trials scoring >2 were deemed to be of high
quality [27]. Concealment to treatment allocation and the
generation of allocation schedules were assessed using
tools developed by Schulz et al. [28] Allocation concealment
was scored as adequate or inadequate, or unclear if there
was insufficient information to make the judgement. For ob-
servational studies, ‘Strengthening the Reporting of
Observational Studies in Epidemiology’ (STROBE) guide-
lines were used to assess quality [29], with close reference
to further elaboration and explanation of the criteria given in
another publication of the STROBE statement [30]. The
STROBE statement contains a checklist of 22 items that
cover the appropriateness of the study’s title, aims, meth-
odology, and adequateness of abstract, results and discus-
sion. Two reviewers (N.M. and M.J.C.) independently
assessed and scored the publications and reached consen-
sus in two cases of disagreement.
Data extraction
Relevant information from the papers was extracted and
presented in tabular form. Because of heterogeneity in the
various predictors and outcome variables, it was not pos-
sible to pool data from the different studies. For each pre-
dictor of interest, the study result was classified as
positive (statistically significant increased likelihood of
either intensity or duration of response), null (no significant
relation of predictor to response) or negative (predictor
associated with significantly worse response).
Results
Search outcome
From all databases, 696 records were retrieved.
Duplicates were eliminated, including those identified
from reference lists of papers and content pages of se-
lected journals (Fig. 1). Text words from 304 journal article
titles were screened, and 203 failed to meet the required
criteria. One hundred and one abstracts and a further 65
full-text articles were read for eligibility. Of the 65 full texts,
54 were rejected for failing to meet the required criteria or
not having predictor data. Eleven publications met the in-
clusion criteria (Table 1).
Ten of the 11 studies were RCTs and 1 was an
observational study. Only two trials [8, 31] had as a pri-
mary aim determination of predictors of response. The
rest of the studies were trials that included evaluation of
predictors of response as part of a secondary or post hoc
analysis of the data. Some studies included only knee OA
with effusion [5, 32] or those without effusion [31], while
others included both [4, 8, 10, 13, 14, 21].
Participants in all the studies were followed for at least 4
weeks. Four looked at longer-term effects up to 612
months [14, 31, 33, 34]. Five of the 10 RCTs were pla-
cebo/controlled trials evaluating steroids such as methyl-
prednisolone acetate (MPA), triamcinolone hexacetonide
(TH) and triamcinolone acetonide (TA) against placebo
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injections. In these trials, only the steroid group’s re-
sponse was used to identify factors predicting response.
One RCT [32] compared treatment effects between two
types of steroid, MPA and TH, another [33] compared
treatment efficacy between tidal irrigation and IASI, two
others [13, 34] compared injection techniques and one
compared blind and US-guided knee injections [31].
When evaluating factors predicting response, outcomes
used in the studies were measurement of pain improve-
ment such as change in Western Ontario McMaster
Universities index (WOMAC) pain scores [4, 10, 33], VAS
pain [5, 8, 21, 31, 32, 34], patient-rated improvement [13]
and Osteoarthritis Research Society International (OARSI)
response criteria [14]. Table 2 summarizes the main pre-
dictor factors and the number of studies that had found
null findings or positive or negative direction of response
to IASI in knee OA.
Data quality
Table 3 contains the Jadad and the allocation conceal-
ment scores of the 10 RCTs. Based on the Jadad
scores, 5 of the 10 studies were high-quality trials.
Based on the STROBE guidelines, the one observational
study scored 14 points out of a maximum score of 22.
Predictors of response
Synovitis
Two studies evaluated synovitis using non-contrast son-
ography [4, 10], though only Pendleton et al. [10] used
power Doppler US, a technique that is better at detecting
synovitis [35] than the grey-scale mode. With the
grey-scale mode it was assumed that synovial hypertro-
phy was synonymous with synovitis [4].
In their RCT, Chao et al. [4] found, among the 34 par-
ticipants who received IASI, that the absence of synovitis,
in comparison with its presence, was associated with a
significant improvement in WOMAC pain subscale at 12
weeks. A single person interpreted the saved images and
synovial hypertrophy was assessed at one location, the
suprapatellar pouch. Pendleton et al. [10] used an obser-
vational study design to study the effect of US-assessed
FIG. 1 Summary of search results.
Not relevant to study questions (n=203)
Duplicates (n=392)
Records identified from all sources (n=696) 
MEDLINE   227 
AMED    173 
CINAHL    178 
Embase    60 
Cochrane Register  34 
Web of Science   13
Others    11
No. of records screened  304 
No. of abstract read  101 
No. of full text read  65 
Not relevant to study questions (n=36)
No. of full text articles excluded (n=54), reasons:
• Review articles       20 
• Steroids adverse effects             13 
• Injection and accuracy      4 
• Not on OA subjects       5 
• Ultrasound assessment      1 
• Anserine Bursitis       1 
• Trials comparing treatment efficacy and not    10 
predictors  
No. of included studies 11     
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synovitis in 86 participants and found it did not predict
response. In a third study based on clinician’s assess-
ment, the presence of synovial thickening (present/
absent) was not associated with a treatment response
[8]. Thus the role of synovitis in predicting response was
unclear.
Effusion
Six studies looked at whether the presence of effusion
was associated with response (see Tables 1 and 2). Of
these six studies, one found effusion, assessed by the
presence of a positive bulge sign and presence of patellar
tap, to be a predictor of improved response when pain
was evaluated using a VAS (P< 0.01 at 1 week, P< 0.05
at 6 weeks) [21]. Although not influencing the magnitude
of response, one other trial found the presence of effusion
(either positive bulge or patellar test) increased the dur-
ation of response [33]. The former study involved SF as-
piration prior to IASI, while the latter included injection of
2 ml of 1% lidocaine with the steroids. In four other trials,
however, there was no association between effusion and
symptom improvement [4, 8, 10, 32]. Again, prior
arthrocentesis [8, 10, 32] within the injection protocol did
not seem to influence subsequent outcomes.
Aspiration
Three of 11 studies evaluated whether aspiration of SF
was associated with treatment response. Gaffney et al.
[21] reported greater improvement in VAS for pain follow-
ing successful SF aspiration (P< 0.01 at week 1). Jones
and Doherty [8] and Shah and Wright [13], in contrast,
failed to find an association between aspiration and treat-
ment response.
Severity of disease
Radiographic severity of OA was found to be a predictor in
two studies; the more severe the disease, the less likely
the patient was to have an OARSI response [relative risk
(RR) 0.59, 95% CI 0.36, 1.0; P< 0.05] [14] or to show
significant change in WOMAC pain score (P< 0.02) [33].
Both these trials used KellgrenLawrence (KL) scores to
grade the OA. In contrast, two other trials that used dif-
ferent OA scoring systems—Dieppe et al. [5] in their trial of
16 participants (grade 14; P-values not given) and
TABLE 3 Quality evaluation of RCTs
Study
Allocation
concealment
Total
Jadad
score
Jadad scoring criteria
Randomized
Double
blind
Description
of drop-outs
or withdrawal
Randomization
is described and
appropriate
Double
blinding is
described and
appropriate
Arden et al. [33] Adequate 3 1  1 1 
Chao et al. [4] Adequate 4 1 1 1  1
Chavez-Chiang et al. [34] Unclear 1 1    
Dieppe et al. [5] Unclear 1 1    
Gaffney et al. [21] Unclear 2 1  1 
Jones and Doherty [8] Unclear 3 1 1 1  
Pyne et al. [32] Unclear 4 1 1 1  1
Shah and Wright [13] Unclear 1 1    
Sibbitt et al. [31] Unclear 2 1  1  
Smith et al. [14] Adequate 5 1 1 1 1 1
TABLE 2 Factors affecting treatment response
Predictor factor
No. of studies showing
positive effect
No. of studies showing
no effect
No. of studies showing
negative effect
Synovitis 0 2a 1
Aspiration 1 2 0
Effusion 2 4 0
Severity of radiographic degeneration 2 2 0
Sonographic-guided injection 1 0 0
Worse pain 1 1 0
Worse stiffness 1 1 0
Worse knee function 1 2 0
Duration of symptom 0 2 0
aOne study used clinical assessment of synovitis.
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Gaffney et al. [21] (scores 09; P-values not given)—did
not find that radiographic OA grading predicted response.
In a further study, arthroscopic grading of cartilage
damage at the time of the steroid injection was not
linked with response (P= 0.3) [14].
Sonographically guided injection
While studies including patients with a variety of rheu-
matic conditions exist, we found only one study of knee
OA, and in that study sonographically guided injections
when compared with blind injections led to a further
42% decrease in absolute pain VAS (P< 0.03) from base-
line scores at 2 weeks, a 1.1-month longer duration of
therapeutic effect (P< 0.01), 107% increase in responder
rate defined by VAS <2 cm (P< 0.001) and 52% reduction
in non-responder rate defined by VAS 52 cm (P< 0.001)
[31]. However, pain outcomes at 6 months were similar
whether these injections were performed blind or sono-
graphically guided.
Other factors potentially affecting response
Local knee tenderness (using a scale ranging from 0 to 3)
was linked with improved response in one study [odds
ratio (OR) 1.80; 95% CI 1.03, 1.67] [8]. In one trial,
higher baseline pain was associated with greater
response to IASI [10] but not in another [21]. Greater base-
line functional impairment was also associated with
improved clinical response, with a higher score of
WOMAC function demonstrating better response at 1
and 6 weeks in one trial [10], but two other studies
found no association between functional scores prior to
treatment and symptom improvement [8, 21]. Pendleton
et al. [10] found a higher WOMAC stiffness score led to
greater response at 1 and 6 weeks. However, in a different
study, morning and inactivity stiffness was not associated
with response to IASI [8]. The presence of patellar tendo-
nitis and local heat was also associated with greater
reduction in night pain [10]. However, Jones and
Doherty [8] did not find that local heat predicted response.
In other studies, chondrocalcinosis [5, 21], crystals and
SF cell counts [5], and SF leucocytes [21] were not linked
with response to IASI. Duration of symptoms did not pre-
dict response [RR 0.91; P= 0.6] in two studies [14, 21].
One study of 59 participants evaluated multiple other
potential predictors age, gender and knee range of move-
ment did not predict response [8]. Maximum isometric
quadriceps strength measured using a commercial strain
gauge and levels of anxiety and depression [assessed
using the Hospital Anxiety and Depression Scale
(HADS)] were not linked to IASI response [8]. Neither
was disability, assessed as composite and lower limb
scores using the Stanford HAQ, associated with IASI
response.
Two other studies investigated whether different injec-
tion sites and approaches influenced outcome from IASI
[13, 34]. Shah and Wright [13] found no differences in the
therapeutic response when 50 mg of hydrocortisone acet-
ate was injected using the infrapatellar or medial knee
approach. Similarly, no difference in outcome was
observed when IASI was delivered using the lateral
mid-patellar approach or through the anterolateral joint
line performed with the knee flexed and needle angled
towards the medial femoral condyle [34].
Discussion
IASI is commonly used to relieve symptoms of knee OA;
however, factors that predict response are poorly charac-
terized, making it difficult to select patients who are most
likely to be successfully treated using this approach. While
this systematic review uncovered inconsistent findings
across studies, there were several features that were
reported by one or more studies as enhancing the like-
lihood of IASI response.
Although the mechanism of the therapeutic effect of
CSs in knee OA is unclear, it is likely related in part to
their potent anti-inflammatory effect. In this context, it is
perhaps surprising that there was no consistent link
between synovitis or presence of effusion on outcome
[4, 8, 10, 32]. Indeed, in one study, the absence of syno-
vitis was linked with a beneficial effect [4]. The difference
in the findings of the two studies that used US-assessed
synovitis [4, 10] also raises questions about whether their
findings were attributable to different patient characteris-
tics and disease severity, different trial design or different
criteria for defining responder status. The Pendleton et al.
[10] study was the larger of the two and included power
Doppler assessments of synovitis, suggesting that its null
findings may be more generalizable.
Methodological limitations in relation to defining the
predictor variables may be another explanation for incon-
sistencies across studies. To assess knee synovitis, direct
visualization and measurement of synovitis through sono-
graphy or other imaging is preferable. In the case of effu-
sion, unsuccessful aspiration may also not always indicate
the absence of effusion [36, 37]. Needle placement out-
side the joint, loculated or highly viscous SF, obese knees
and errors from injectors all affect the ability to aspirate
fluid [37, 38]. Even when the needle has been successfully
placed within the joint capsule, it can move into the syno-
vium or fat pad, resulting in a dry tap [38]. Medial knee
plica can also obstruct aspiration [38], and it has been
reported that fluid may be inaccessible if present in low
volume [37, 38]. In relation to SF, small effusion volumes
may not be readily detectable during clinical assessment.
When using US to assess the presence of knee effusion,
SF volume <7 ml, which is equivalent to about 2 mm
thickness, may not be discernible during scanning [39,
40]. In some knees, effusion may be localized in the supra-
patellar pouch or the medial or lateral recesses of the knee
[40, 41], hence restricting US assessment to only one
region may result in false-negative findings.
Surprisingly, there were only a few studies that formally
studied the effect of the severity of joint and cartilage
degeneration in knee OA on treatment response. Trials
that used KL grading of knee OA appeared to find positive
findings [14, 33], while those that used other scoring sys-
tems had null results [5, 21]. Smith et al. [14] also did not
find arthroscopic grading of cartilage damage associated
with treatment response, despite the fact that the same
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trial found more severe disease, as assessed radiographi-
cally, to be associated with a worse response. This trial
was an investigation of the effect of IASI given at the time
of arthroscopy, where the adjunct treatment of arthro-
scopy could be a variable affecting outcome.
One major reason for null findings of studies is that most
of the studies included in our review had too few subjects
to be likely to detect significant risk factor effects, even if
these effects were of clinical importance. We estimate
that a sample size of 93 would be needed to ensure an
80% likelihood of detecting a factor with a prevalence of
50% to increase the odds of response to steroids 2-fold.
Only 1 of the 11 studies had a sample size that was this
large. The small-study bias could partially explain the con-
flicting results for the different predictors.
We are unable to evaluate whether the duration of
follow-up in our studies accounts for some of the null
findings in terms of predictors. The studies in general
examined patients anywhere from 1 week to several
weeks after injection, but a few studies looked at patients
as late as 6 months after injection. In these latter studies,
there were earlier evaluations and we focused on them, to
be consistent.
Another consideration is whether the different steroids
used in the trials partially explain the conflicting results for
each outcome. Triamcinolone acetate, MPA and TH are
said to share similar potency with similar recommended
dosing [42]. Trials that have evaluated different steroid
preparations in knee OA have not found significant differ-
ences among the various IA steroids [15, 32, 4345].
However, one trial indicated that TH might act more
quickly and could lead to a greater reduction in pain
than MPA in the first 3 weeks after the injection [32]. The
studies reviewed in this article of IASI predictors were
primarily those using MPA, TH and TA (see Table 1) and
differences in steroids should not have affected the results
examining other predictors, although we cannot exclude
the possibility that differences in doses across the studies
would have affected the durability or intensity of steroid
response. None of the studies we reviewed formally eval-
uated dose response for the commonly used IA steroid
preparations in knee OA.
The sparse evidence for factors that may influence IASI
reflected from this systematic review is partly because
predictor factors are understudied. We could only identify
11 publications, of which many of them evaluated predic-
tor factors as part of a secondary or post hoc analysis of
the data. Secondly, predictor factors are poorly studied in
trials. Many of the trials identified in this review were RCTs
but the design of placebo/control comparisons of treat-
ment effects of steroids means that evaluation of predic-
tors of response to IASI can be made on one group only,
the group that received the IASI, while the control/placebo
group is disregarded. As evaluation of the predictor fac-
tors was now confined to the treatment group, this
reduced further the sample size on many of the already
small trials such that even if there is a predictor factor
present, the power of the study would not be sufficient
to detect it. This raises the question of whether RCT is
the primary design for predictors of response. A longitu-
dinal design such as observational studies, in contrast,
may have allowed study of a wider spectrum of the dis-
ease and overcome some of the main constraints faced
by RCTs.
To find additional studies, we expanded the search to
trials that compared other agents such as hyaluronate
with steroids in knee OA, but we were unable to find pre-
dictor studies on IASI among them. The use of Jadad
scores may not provide the best evidence for quality
[46] but our findings using scoring systems for individual
items evaluating quality did not differ much from the
Jadad scores, since many of these trials lacked aspects
of methodological rigour.
Other potential predictors, including previous knee
injections, BMI, knee joint misalignment, use of walking
aids, presence of muscle atrophy and also socio-eco-
nomic factors have not been investigated. Future studies
should include sufficient numbers of patients to provide
adequate power and a longitudinally designed large
observational study may be more appropriate to study
IA steroid predictor factors. There should be clear infor-
mation about the methods used to determine putative
predictors and also details about the intervention, includ-
ing delivery of therapy and whether or not US was used.
Standardized outcomes should be reported, including
pain, stiffness and function.
In summary, to our knowledge this is the first systematic
review that attempts to investigate factors that may pre-
dict response to IASI in knee OA. Because of heteroge-
neity (in exposures), it was not possible to pool data
across studies. Data from individual publications,
although not consistent across studies, indicated there
could be a number of predictors of response to IASI,
including effusion, withdrawal of fluid from the knee,
absence of synovitis, delivering injections under US
guidance, structural severity of disease and pain. Further
studies using standardized methods of assessment are
needed to confirm these predictor factors and to
characterize treatment response to IASI in patients with
knee OA. Such data will be of help in better targeting
therapy to those most likely to benefit.
Rheumatology key messages
. This is the first systematic review to consider clin-
ical predictors of response to IASI in knee OA.
. No consistent predictors of response were identi-
fied for IASI in knee OA.
. Further studies are required to characterize predic-
tors of response to IA steroid therapy in knee OA.
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